Funding for this research was provided by:
Northern Ontario Academic Medicine Association (A-17-05)
Received: 1 March 2019
Accepted: 21 May 2019
First Online: 26 June 2019
Change Date: 6 November 2019
Change Type: Correction
Change Details: Following publication of the original article , we have been notified that the following changes should occur in the content of the article. The details are below.
Ethics approval and consent to participate
: Data was obtained by submitting a formal requisition to IC/ES. The data were accessed remotely using a secure server located at IC/ES. The study was approved by the Research Ethics Board of Laurentian University in Sudbury.
: Not applicable – all data for this study was secondary data from administrative datasets. All data was de-identified.
: Dr. David Marsh maintains the following roles: Chief Medical Director at CATC (Canadian Addiction Treatment Center), opioid agonist therapy provider. Dr. Marsh has no ownership stake in the CATC as a stipendiary employee. We do not foresee any conflict of interest as data will be made freely available to the public and the CATC, and the Universities have no ability to prevent publication and dissemination of knowledge. The authors declare that they have no competing interests. The authors declare that they have no competing interests.